Skip to main content

Targeted therapies for EBV-positive nasopharyngeal cancer

Current therapies show limited efficacy for EBV-positive nasopharyngeal cancer. Targeting EBV oncoproteins presents a promising therapeutic avenue, but challenges such as delivery mechanisms and dose toxicity must first be addressed.

Read more

Editor's Choice

An extremely rare subtype of lymphoma

Primary pulmonary DLBCL is a rare clinical condition with nonspecific clinical manifestations, posing significant challenges for diagnosis. This patient was initially misdiagnosed as having organizing pneumonia.

Biomarkers of response to immunotherapy in SCLC

  • Free for a limited time
  • SCLC
  • Review

Traditional biomarkers are not useful for guiding immunotherapeutic decision-making in small-cell lung cancer. So what biomarkers could help? Explore the evidence from preclinical and clinical studies.

Detection bias may explain short-term thyroid cancer risk with GLP-1 receptor agonist use

People with type 2 diabetes beginning GLP-1 receptor agonist therapy have a short-term increased risk of thyroid cancer compared with those who initiate alternative diabetes medications.

Second-line treatment for metastatic TNBC

What is the best second-line treatment option for metastatic triple-negative breast cancer? The review authors assess and summarize the evidence from clinical trials to answer the question.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Episode 15: Breastfeeding after breast cancer

POSITIVEly reassuring results from a clinical trial

The POSITIVE trial previously showed that women with breast cancer can safely interrupt endocrine therapy in order to become pregnant. But what about breastfeeding - is that possible and safe for the mother and baby?

Women can take heart from the latest findings, says Dr. Cristina Saura, as she takes us through these important clinical updates.

Dr. Cristina Saura
Listen now
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now

Case Studies

An extremely rare subtype of lymphoma

Primary pulmonary DLBCL is a rare clinical condition with nonspecific clinical manifestations, posing significant challenges for diagnosis. This patient was initially misdiagnosed as having organizing pneumonia.

Immune checkpoint inhibitor-related diabetes

ICI-related diabetes developed after 18 months of nivolumab treatment for malignant melanoma. Diffusion-weighted imaging may provide valuable insights into pancreatic involvement at an early stage of the disease.

A fatal side effect of a novel drug

Following treatment with the bispecific T-cell engager epcoritamab, a patient with relapsed DLBCL developed pleural effusion, which proved fatal despite aggressive management. Regular monitoring is crucial to identify and manage severe inflammatory reactions.

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Current Reviews

Imaging in clinical trials for psoriatic arthritis: a scoping review

Psoriatic arthritis (PsA) is a chronic inflammatory condition principally affecting the skin and musculoskeletal system, associated with comorbidities and decreased quality of life. Imaging is crucial for diagnosis, monitoring progression, and …

Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges

Endometrial cancer (EC) is the sixth-most common cancer in women, with over 427,000 newly diagnosed cases globally in 2022 [ 1 ]. An increasing number of young patients are choosing to undergo fertility-preservation treatment. The guidelines …

From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections

The prostate gland is an endocrine-sensitive organ responding to multiple stimuli. Its development and function are regulated by multiple hormones (i.e. steroids such as androgens, estrogens and glucocorticoids) but also by other key hormonal …

Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies

Hepatocellular carcinoma (HCC) remains a significant global health challenge, with over 800,000 new cases diagnosed annually. This comprehensive review examines current surgical approaches and emerging multidisciplinary strategies in HCC …

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Read more

CME & eLearning

SPONSORED

Webinar

1.5 European CME credits (ECMEC®s)

A series of patient cases underpin this interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.

Sponsored by:
  • Kyowa Kirin
Developed by: Springer Healthcare

Symposium (Link opens in a new window)

An independent symposium at the 10th COMy World Congress focusing on BCMA-targeting strategies for the treatment of multiple myeloma. Gain insights into the latest clinical data and the implications for clinical practice.

Supported by:
  • GlaxoSmithKline
Developed by: Springer Healthcare IME

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME

Further Reading

Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria

The incidence of leukemic conversion during the clinical course of paroxysmal nocturnal hemoglobinuria (PNH) has been reported to be 0.6–2.9%. Such an association is logically linked to the progression of PNH to acute leukemia, especially the M6 …

Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry—clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression

This is an annual report by the Japanese Breast Cancer Society, which provides statistics on the clinical data on breast cancer in Japan, extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR). This report includes an …

Road to Hepatitis C Elimination in Israel: Improvements in Linkage to Care (2009–2020)

Hepatitis C virus (HCV) infection remains a major cause of morbidity and mortality worldwide. Following the elucidation of the virus genomic structure, effective direct-acting anti-viral (DAA) drugs have been developed, with sustained virological …

Impact of metastasectomy on survival in patients with oligometastatic stage 4a lung cancer: a retrospective analysis

The aim of our study is to evaluate the impact of metastasectomy on survival in patients with oligometastatic stage 4 lung cancer. Fifty-nine oligometastatic lung cancer cases operated on in our clinic between January 2015 and January 2024 were …

Related topics

An extremely rare subtype of lymphoma

Primary pulmonary DLBCL is a rare clinical condition with nonspecific clinical manifestations, posing significant challenges for diagnosis. This patient was initially misdiagnosed as having organizing pneumonia.

Read more

Targeted therapies for EBV-positive nasopharyngeal cancer

Current therapies show limited efficacy for EBV-positive nasopharyngeal cancer. Targeting EBV oncoproteins presents a promising therapeutic avenue, but challenges such as delivery mechanisms and dose toxicity must first be addressed.

Read more